Neurotech’s NT-501 moves to final tests

LINCOLN – Neurotech Pharmaceuticals Inc. plans to move into the final stage of development on its top product candidate, NT-501, after a second round of clinical trials ended with positive results. If the final stage of testing goes well, the biopharmaceutical company, which focuses on the development of treatments for chronic eye diseases, can seek…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display